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Abstract 
In this paper, we present a spatio-temporal mathematical model for simulating the formation and growth of a thrombus. Blood 
is treated as a multi-constituent mixture comprised of a linear fluid phase and a thrombus (solid) phase. The transport and 
reactions of 10 chemical and biological species are incorporated using a system of coupled convection-reaction-diffusion (CRD) 
equations to represent three processes in thrombus formation: initiation, propagation and stabilization. Computational fluid 
dynamic (CFD) simulations using the libraries of OpenFOAM were performed for two illustrative benchmark problems: in 
vivo thrombus growth in an injured blood vessel and in vitro thrombus deposition in micro-channels (1.5mm × 1.6mm × 
0.1mm) with small crevices (125m × 75m and 125m × 137m). For both problems, the simulated thrombus deposition 
agreed very well with experimental observations, both spatially and temporally. Based on the success with these two benchmark 
problems, which have very different flow conditions and biological environments, we believe that the current model will 
provide useful insight into the genesis of thrombosis in blood-wetted devices, and provide a tool for the design of less 
thrombogenic devices. 
Introduction 
The hemostatic response at the site of vascular injury prevents the loss of blood, but excessive thrombosis may impede or 
interrupt blood flow to vital organs and tissues. The development of a thrombus in the vasculature is associated with myocardial 
infarction and stroke, as well as venous thromboembolic disorders.1,2 Thrombus formation in blood-contacting medical devices 
is a common cause of failure, and one of the most significant sources of morbidity and mortality.3,4 For instance, thrombosis in 
patients receiving ventricular assist devices (VADs) is one of the leading adverse events associated with this therapy, and has 
raised concerns in the medical community5–8 and with regulatory bodies such as the FDA9. Therefore, there is a critical need 
for improved understanding of the conditions under which hemostatic pathways may proceed to an excessive and undesirable 
thrombotic response. 
Thrombosis is a complex phenomenon in which a combination of interrelated biochemical and hemodynamic factors result in 
several cascade reactions causing platelet activation, deposition, aggregation, and stabilization10–12. The complexity is 
accentuated by several feed-forward and feedback mechanisms promoting and inhibiting coagulation reactions. Therefore a 
comprehensive description of thrombus generation requires a model which can account for interrelated reactions involving 
platelet activation and aggregation, transport of platelets and chemical species in flow, and the interaction between the formed 
thrombus and the flow field 10,13–17. The large number of chemical species and the complexity of cascade reactions make it very 
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difficult to synthesize a comprehensive picture of coagulation dynamics using traditional laboratory approaches 16. This 
motivates the pursuit of mathematical models 13,17–23.  
For practical objective of predicting thrombosis in blood-wetted medical devices there is inevitably a tradeoff between 
complexity and utility. An overly simplistic model may fail to account for the essential mechanisms listed above. However, an 
overly complex model that includes the numerous biochemical species and pathways of coagulation may contain many 
unidentified parameters, and therefore be intractable or indeterminate to compute. A reasonable compromise was formulated 
by Sorensen et al. in which a set of convection-reaction-diffusion equations were employed to simulate platelet activation. This 
model featured a weighted linear combination of agonist concentrations, agonist release and synthesis by activated platelets, 
platelet-phospholipid-dependent generation of thrombin, and thrombin inhibition by heparin 13,14. All of the parameters 
employed in Sorensen's model were available from the experimental literature or by calibration with experimental data. 
However, this model has several shortcomings limiting its versatility, namely: (1) it limits platelet deposition to an idealized, 
unchanging surface-fluid boundary and does not account for alterations in the flow field due to thrombus growth, (2) it neglects 
shear-induced platelet activation, and (3) it does not include thrombus embolization (erosion) due to shear. These limitations 
motivated the development of a more sophisticated model that could build in these important mechanisms in the thrombotic 
process. 
Results 
Platelet deposition in blood vessel  
The simulation of thrombus deposition in a blood vessel was modeled by assuming initial laminar flow in a straight, cylindrical 
blood vessel, shown in Figure 1, that was defined to represent the seminal in-vivo experiments of Begent and Born 24 and Born 
and Richardson 25. In these experiments, thrombosis was initiated within a blood vessel of the hamster by injecting ADP at a 
localized injury site. The diameter and length of the simulated vessel was 0.06mm and 0.5mm, respectively. The mean velocity 
was 800𝜇𝑚/𝑠 by prescribing a pressure difference between inlet and outlet, corresponding to a Reynold’s number of 0.14. The 
surface properties were assumed to be those of healthy endothelium, with the exception of the injured injection site, which was 
assumed to be highly adhesive to platelets. The corresponding reaction rates at the boundary were prescribed as 𝑘𝑟𝑝𝑑,𝑏 = 4.0 ×
10−5m/s and 𝑘𝑎𝑝𝑑,𝑏 = 4.0 × 10
−4m/s, and the characteristic embolization shear rate was 𝜏𝑒𝑚𝑏,𝑏 = 1.0 𝑑𝑦𝑛𝑒 𝑐𝑚
−2. (For the 
physical meaning of the terms/parameters, please see the tables in methods section and Supplemental Appendix.) The 
comparatively large value of 𝑘𝑎𝑝𝑑,𝑏 = 4.0 × 10
−4m/s ensured that activated platelets nearby are efficiently captured by the 
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injured site. The platelet deposition rate at the surface, 𝑘𝑟𝑝𝑑,𝑏was chosen based on the platelet-collagen deposition rate provided 
by Sorensen13,14. The platelet-platelet aggregation rates, 𝑘𝑟𝑎 = 3.0 × 10
−6m/s , 𝑘𝑎𝑎 = 3.0 × 10
−5m/s , were based on 
Sorensen et al. as well13,14. The characteristic embolization shear rate was 𝜏𝑒𝑚𝑏 = 30 𝑑𝑦𝑛𝑒 𝑐𝑚
−2 based on Goodman et al21. 
The boundary reaction rates for normal, healthy endothelium were set to zero. All remaining parameters are provided in the 
Table 6. The inlet [RP] and [AP] were prescribed 6 × 1014PLTs/m3 and 6 × 1012PLTs/m3 respectively, based on normal 
values for rodents.26,27 The [RP] and [AP] are the unactivated resting platelets and activated platelets in flow respectively. 
Figure 2 provides a snapshot of the growing thrombus at t=200s. Comparison of the simulation results with experimental 
observations of Begent and Born 24 were made on the basis of thrombus growth rate, shape, and size, (see Figure 3-5). Figure 
3 illustrates the progression of thrombus growth in the simulation. According to Begent and Born 24, the thrombus grew to a 
height of 1/3 the lumen diameter in approximately 100-200s, while the same size was obtained after about 150s in our 
simulation. Figure 5 shows the comparison of the height versus the length of the thrombus observed experimentally and 
numerically. We found that the model accurately predicted the shape (aspect ratio) of the growing thrombus, which was 
approximately 2.5:1 (length:height) throughout its growth. The deviation between the experiments and simulations may be 
attributed to some level of uncertainty in the in vivo experiments. According to Begent and Born24,25, the data were derived 
from different experiments where the conditions, such as flow rate and vessel geometry, may have varied slightly. Qualitatively, 
it was observed that the thrombus grew both upstream and downstream of the injection site, which also agrees with the 
experimental observations. (See Figure 4.) The upstream growth may be due to the capture of the incoming platelets and the 
relatively low shear rates; while downstream growth is supplied by platelets activated upstream.  
 
Figure 1 Schematic of the simulated blood vessel of Begent and Born 24 and Born and Richardson 25. The ADP injection port is located at the 
bottom vessel wall (diameter = 3𝜇𝑚). The surface properties are assumed to be those of healthy endothelium, with exception of the injection 
site at which there is an elevated rate of platelet adhesion. 
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Figure 2 Snapshots of simulated thrombus and streamlines at t=200s with a mean velocity 800𝜇𝑚/𝑠. The unit of the color scale bar is 
𝜇𝑚/𝑠. 
 
Figure 3 Orthographic views (front and side) of the progression of thrombus growth and velocity field evolution in a circular vessel at a 
mean velocity 800𝜇𝑚/𝑠. The side view crosses the plane A-A shown in Figure 1. The arrows indicate the position of the ADP injection 
port. The unit of the scale bar is 𝜇𝑚/𝑠. 
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Figure 4 Thrombus in blood vessel observed by Begent and Born 24 after approximately 100-200s of ADP injection through micropipette. 
The figure is reused by permission.  
 
Figure 5 Thrombus height vs length by numerical simulation and experiments at a mean velocity 800𝜇𝑚/𝑠. Experimental data are from 
Born et al. 24,25. 
Figure 6 shows the streamlines, shear rate, and concentration fields of the 8 remaining species on the radial-axial slice plane. 
The streamlines indicate that the fluid velocity within the region occupied by the thrombus is zero. Consequently, this produces 
a stenosis within the vessel. Figure 6(b) indicates a concentration of shear near the surface of the thrombus, which opposes 
platelet deposition. Figure 6(c) indicates that the concentration of activated platelets in flow is greatest at the leading and trailing 
edges of the thrombus. Figure 6(e) shows the concentration of the deposited activated platelets where we can find that the 
concentration in the thrombus core is comparatively higher, which is similar to the observation of Stalker et al. 28. Figure 6(f) 
illustrates the diffusion of ADP from the injection site through the thrombus. The concentration of ADP on the surface activates 
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resting platelets which causes the propagation of thrombus growth. Figure 6(g-h) indicates the synthesis of platelet agoinists, 
TxA2 and thrombin by deposited platelets in the interior of the thrombus. Accordingly Figure 7(i-j) illustrates that prothrombin 
and anti-thrombin III (ATIII) are consumed in the interior of the thrombus.  
 
 
 
 
 
Figure 6 Streamlines, shear rate and concentration fields within the centerline plane at t=200s. It should be noticed that the total activated 
platelets contain the resting AP shown in figure (c) and deposited AP shown in figure (e). 
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Additional simulations were performed to study the rate, and time for complete occlusion of the vessel. Table 1 shows that 
blocking all platelet agonists highly suppresses thrombus growth, and blocking of ADP or Thrombin (TB) increases the 
occlusion by almost a factor of 2. In contrast, the blocking of TxA2 has a negligible effect on occlusion time. Figure 7 provides 
the time course of platelet deposition, as measured by the total thrombus volume. We observed that the simulations predict a 
sigmoidal rate of deposition: initially slow, rapidly increasing until the vessel is completely occluded, at which point the 
thrombus continues to grow longitudinally at a slower rate. This pattern closely resembles the in-vivo observations of Mangin 
et al.28 in the blood vessel of a rat. An additional interesting observation from Figure 7 is that for the case where ADP is blocked, 
the total thrombus volume at the time of occlusion is greater than the other cases. This implies that for this case, axial thrombus 
growth occurs more quickly than for the other cases. 
Table 1 Time to vessel occlusion by thrombus under varying conditions. For all of the cases there was an injured site as shown in Figure 1, 
and all unmentioned conditions were the same as for the case studied previously24,25. The first case of Begent and Born implies no agonists 
were blocked, an injured site was present and ADP was injected at the injured site. 
Case  Occlusion time 
ADP injected (same as Begent and Born 24,25.) 340s 
No ADP injected. 380s 
No ADP injected and with blocking of ADP. 590s 
No ADP injected and with blocking of TB. 620s 
No ADP injected and with blocking of TxA2. 380s 
No ADP injected and with blocking of all agonists. N/A; (Up to 1200s.) 
 
Figure 7 Time course of thrombus formation (volume) to total vessel occlusion with different agonists blocked. The plateaus exhibited by 
most of the cases correspond to occlusion of the vessel, followed by gradual growth, driven primarily by diffusion.  
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Platelet deposition in a micro-crevice  
The second benchmark problem, a rectangular channel with a micro crevice, was motivated by a persistent problem involved 
in most blood wetted medical devices, namely the seams and joints between component parts that are well known to be 
predisposed to thrombus deposition. The simulation was formulated to replicate a microfluidic experiment reported previously 
that utilized human blood 29,30 (See Figure 8). The overall half-height of the channel was 1.5mm, and the depth 0.1mm. The 
modeled domain only included a portion of the overall 3cm length of the experimental channel. The height of the crevice was 
0.125mm and the lengths of the crevice studied here were 𝐿𝑐 = 0.075𝑚𝑚  and 𝐿𝑐 = 0.137𝑚𝑚 . The inlet velocity was 
prescribed as 0.0173m/s, corresponding to a Reynolds number of 32.3. The reaction rates and characteristic embolization shear 
rates were the same as the previous simulation. However the boundary reaction rates and embolization rate needed to be 
adjusted to account for the different material properties (titanium alloy, Ti6Al4V): 𝑘𝑟𝑝𝑑𝑏 = 1.0 × 10
−20m/s, 𝑘𝑎𝑝𝑑𝑏 = 1.0 ×
10−5m/s, 𝜏𝑒𝑚𝑏𝑏 = 0.1 𝑑𝑦𝑛𝑒 𝑐𝑚
−2. The value of 𝑘𝑟𝑝𝑑𝑏 implies no deposition occurs for resting unactivated platelets, and the 
values of 𝑘𝑎𝑝𝑑𝑏 and 𝜏𝑒𝑚𝑏𝑏 were chosen by best fitting the results of the case with 𝐿𝑐 = 0.075𝑚𝑚. The inlet [RP] and [AP] 
was prescribed as 2.5 × 1014PLTs/m3 and 1 × 1013PLTs/m3 respectively, corresponding to nominal values for human blood. 
Figure 9 shows the deposited platelet field based on the numerical simulation and experiments with the crevice length 𝐿𝑐 =
0.075𝑚𝑚 at t=300s and 450s. The first column is a three-dimensional rendering of the accumulated thrombus. The second 
column is the simulated volume fraction of platelets on the near wall, corresponding to the field of view of microscopic 
observations of fluorescently labelled platelets. 31,32 Comparison of simulation and experiment reveals very good agreement, 
particularly the thrombus growth at the leading and trailing edges of the crevice. Keeping all the conditions consistent, an 
additional simulation was performed in channel with a longer crevices (𝐿𝑐 = 0.137𝑚𝑚.) Figure 10 shows the corresponding 
deposited platelets at t= 300 and 450s. Compared to Figure 9, it is clear that lengthening the crevice dramatically reduces the 
rate of deposition, which is consistent with experimental observations.   
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Figure 8 Schematic of the computational domain for rectangular microfluidic channel with a crevice. The overall half-height of the channel 
was 1.5mm, and the depth is 0.1mm. The domain only included a portion of the overall 3cm length of the experimental channel. The height 
of the crevice was 0.125mm and lengths, 𝐿𝑐, of the crevices were 0.075mm and 0.137mm. The inlet velocity was 0.0173m/s (Re=32.30). A 
and B indicate upstream and downstream corners of the crevice, respectively. 
 
Figure 9 Comparison of thrombus deposition by simulation versus microscopic experiment at t=300 and 450s with crevice length 𝐿𝑐 =
0.075𝑚𝑚. Left panel is a 3D rendering of the simulated thrombus. Center and right panels indicate volume fraction of platelets in the near-
wall region of the channel.  
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Figure 10 Comparison of thrombus deposition by simulation versus microscopic experiment at t=300 and 450s with crevice length 𝐿𝑐 =
0.137𝑚𝑚. Left panel is a 3D rendering of the simulated thrombus. Center and right panels indicate volume fraction of platelets in the near-
wall region of the channel. The figures are reused by permission. 30 
Figure 11 shows the progression of the simulated thrombus deposition from 300-600s illustrating the growth of both upstream 
and downstream thrombi with the crevice length of 0.075mm. The downstream corner of the crevice has been indicated as the 
region where the thrombus grows earliest and fastest, (Figure 11). This may be because at the rear corner, except for the platelets 
which were activated locally, many platelets are activated without being deposited at the beginning corner. These platelets are 
transported to the rear corner where they are captured. This makes the growth rate of the thrombus at the rear corner much 
faster. When the deposited thrombus at the rear corner accumulates to a certain, rather large value, the agonists produced by 
those deposited platelets become concentrated enough to activate the unactivated surrounding platelets. In this region, the 
amount of the platelets activated by agonists will be much larger than those activated by the shear stress, which indicates an 
even faster thrombus deposition at the rear corner. Figure 12 provides the streamlines, shear rate and snapshot of concentration 
fields of the different species in the model. These figures indicate an accumulation of agonists and activated platelets within 
the cavity. Once thrombi begin to deposit at the leading and trailing edges, it appears that the secondary vortex within the cavity 
transports the activated platelets whereupon they accumulate with the deposited platelets in these two regions.  
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Figure 11 Evolution of thrombus growth in rectangular crevice. The length of the crevice is 0.075mm. 
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Figure 12 Streamlines, shear rate and concentration fields within the x-y slice plane at distance from the wall z=10𝜇𝑚, at t=600s. The 
length of the crevice is 0.075mm. 
Discussion 
Mathematical models to simulate blood coagulation and thrombosis have steadily increased in complexity over recent 
decades.13,16,20,23,33–35 Paradoxically, parallel efforts have been made to reduce the order, and hence complexity, of thrombosis 
models36,37. The appropriate level of complexity depends on the application for which the model is intended, and the questions 
being asked. For predicting thrombosis in blood wetted devices, the bare minimum that a model should include are the 
fundamental components of Virchow’s triad: (1) the properties of blood, including several states for platelets, biochemical 
agonists with associated positive feedback mechanisms, and agonist inhibition; (2) the character of flow which includes shear-
mediated platelet activation, species convection, and thrombus-fluid interaction; and (3) surface chemistry in terms of surface 
reactivity.  
Models commonly used today also encompass a wide range of physical scales and degree of granularity, each with advantages 
and disadvantages. In general, micro-scale models are more appropriate for studying phenomena that occur within and between 
individual cells.19,20 Such models typically involve many unknown parameters. For this reason, phenomenological models are 
more practical, yet they are limited by the assumptions necessary to account for un-modeled behavior at the micro-scale. The 
thrombosis model presented here adopts a continuum approach that seeks to achieve a compromise in complexity and scale. 
The advantage of this approach is scalability, which enables simulation of arbitrarily shaped, complicated geometries that are 
encountered with the blood flow pathways of many current medical devices. To account for the most essential cell- and 
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molecular scale mechanisms, this model employs a set of convection-diffusion-reaction equations that represent platelet 
activation by both chemical agonists and fluid forces; platelet deposition; thrombus propagation; thrombus embolization; 
thrombus stabilization; and inhibition. This model builds upon many of the principles incorporated in the earlier work of 
Sorensen et al. 13,14, and inspired by the pioneering work of Fogelson 38. Although the Sorensen model demonstrated good 
results in simulating platelet deposition in simple parallel-plate flow 13,14, it lacked several features that limited its versatility. 
Accordingly, this revised model added shear-induced platelet activation, thrombus embolization due to shear, and fluid-solid 
interaction with the growing thrombus. The resulting number of species in the transport model was increased from 7 to 10. 
Similar to Sorensen, the current model derived most parameters from literature. The only parameters that were determined by 
experimental fitting were the three surface-specific coefficients, namely 𝑘𝑟𝑝𝑑,𝑏, 𝑘𝑎𝑝𝑑,𝑏 and 𝜏𝑒𝑚𝑏,𝑏. If the model were to be used 
with different materials, such as polycarbonate or stainless steel, these three terms would need to be modified. Likewise, some 
parameters would need to be adjusted for viscosity, animal species, and various pathologies.  
Although this model performed well with the two representative problems studied, it would still benefit from additional 
validation in different scenarios, such as vascular stenosis 39,40, sudden expansions 32, and other architectures with a broader 
range of flow conditions and blood properties 19,41,42. It might be found that some assumptions and simplifications will need to 
be revisited. For example, we have modeled the blood as a single phase fluid, ignoring the spatial distribution of RBCs. This 
was done for the sake of numerical stability and in consideration of more complex future applications of the model. It is widely 
known that platelets tend to concentrate near the vessel wall, due to the interaction with RBCs, which can influence the rate of 
thrombosis43–45. The opposite is also possible: some experimental studies have also found that collisions of RBCs with thrombi 
reduced their mass46. These phenomena may have been compensated to some extent by choosing an appropriate deposition 
rates in the current work. Furthermore, the current model excluded the influence of von Willebrand factor, which is known to 
be relevant in platelet deposition in high-shear field devices such as blood pumps.47–50 Also, the thrombus stabilization rate was 
assumed to be negligible in the current simulations. Consequently, thrombus growth was limited as deposition reached 
equilibrium with clearance by shear. However, for problems where deposition occurs over a long period of time, stabilization 
may play an essential role. Capturing this phenomenon is a challenge, since the process involves several chemical and biological 
species, such as fibrinogen/fibrin and factor XIII, which would increase the number of parameters. 48,51,52 Such an effort is a 
focal point for our ongoing work. The reader interested in fibrin formation and thrombus stabilization is referred to recent 
experimental reports by Colace, Neeves, and Savage 53–55 and the theoretical model of Anand et al. 18. 
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In its current embodiment, the thrombosis model presented here was able to replicate the patterns of platelet deposition in a 
micro-crevice observed experimentally. Both experiment and simulation revealed a counter-intuitive growth of thrombus from 
both edges (corners) of the crevice. The simulation however revealed the underlying processes by which an initial platelet 
deposition serves as a nidus for continued thrombus growth through the activation of resting platelets, generation of thrombin, 
and a temporal influence on the regional fluid dynamics. These results provide evidence that this model may find application 
in examining the influence of various hemodynamic and biochemical factors on the undesirable phenomenon of thrombotic 
deposition in medical devices.  
Conclusions 
We have presented a mathematical model for simulating the initiation and propagation of thrombus formation on biomaterial 
surfaces. The model demonstrated excellent agreement with two illustrative benchmark problems: in vivo thrombus growth in 
an injured blood vessel and an in vitro thrombus deposition in micro-channels with small crevices. Because the model includes 
several interrelated biochemical and hemodynamic mechanisms, it was also able to simulate the influence of downregulating 
(blocking) certain biochemical agonists, such as ADP, thrombin, and TxA2. Using the model, we were able to predict the 
influence of a small crevice in the blood flow path, similar to those frequently found at the seams and joints between component 
parts of a blood-contacting medical device. By repeated simulations with a range of hemodynamic, biochemical, and geometric 
conditions, it is hoped that the model will prove useful as part of a broader design process seeking to create more blood 
biocompatible medical devices. 
Methods: Mathematical Model 
We introduce a mathematical model of thrombosis consisting of equations of motion that determine the pressure and velocity 
fields and a set of coupled convection-diffusion-reaction (CDR) equations that govern the transport and inter-conversion of 
chemical and biological species – both within the thrombus and in the free stream.  
Equations of motion 
Blood is treated as a multi-constituent mixture comprised of (1) a fluid phase which is modeled as a linear fluid and (2) a 
thrombus phase. The fluid phase comprises red blood cells (RBCs) suspended in plasma, and is governed by the following 
equations of conservation of mass and linear momentum:  
𝜕𝜌𝑓
𝜕𝑡
+ 𝑑𝑖𝑣(𝜌𝑓𝒗𝑓) = 0 (1) 
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𝜌𝑓
𝐷𝒗𝑓
𝐷𝑡
= 𝑑𝑖𝑣(𝑻𝑓) + 𝜌𝑓𝒃𝑓 − 𝐶2𝑓(𝜙)(𝒗𝑓 − 𝒗𝑇) (2) 
where 𝑻𝑓  is stress tensor of the fluid, represented by: 
𝑻𝑓 = [−𝑝(1 − 𝜙)]𝑰 + 2𝜇𝑓(1 − 𝜙)𝑫𝑓 (3) 
where 𝑝 is the pressure, 𝜇𝑓 is the asymptotic dynamic viscosity (3.5cP). A scalar field 𝜙 is introduced to represent the volume 
fraction of deposited platelets (thrombus). The density of the fluid phase is defined in terms of the volume fraction according 
to: 
𝜌𝑓 = (1 − 𝜙)𝜌𝑓0 (4) 
where 𝜌𝑓0 is the density of the fluid phase (= 1060 kg/m
3), 𝒃𝑓 is the body force, 𝒗𝑓 and 𝒗𝑇 are the velocity of the fluid and 
thrombus phases, respectively. Therefore the term 𝐶2𝑓(𝜙)(𝒗𝑓 − 𝒗𝑇) is the resistance force on the fluid phase from the 
thrombus, where the coefficient 𝐶2 = 2 × 10
9𝑘𝑔/(𝑚3𝑠) is computed by assuming deposited platelets behave like densely 
compact particles 2.78um in diameter, described by Johnson et al. 56 and Wu et al.57,58, and 𝑓(𝜙) = 𝜙(1 + 6.5𝜙) is the 
hindrance function.  
Convection-diffusion-reaction equations 
The current model includes ten (10) chemical and biological species, summarized in Tables 1 and 2, and illustrated in Figure 
1. These include five categories (states) of platelets (1) RP: resting platelets (in the flow field); (2) AP: activated platelets (in 
the flow field, and more reactive); (3) RPd: deposited (trapped) resting platelets, (4) APd: deposited active platelets, and (5) 
APs: deposited and stabilized platelets. An additional five biochemical species include (1) apr: platelet-released agonists (ADP), 
(2) aps: platelet-synthesized agonist (thromboxane A2), which can be degraded via first-order reactions; (3) PT: prothrombin; 
(4) TB: thrombin, synthesized from prothrombin on the activated platelet phospholipid membrane; and (5) AT: anti-thrombin 
III, which inhibits thrombin and whose action is catalyzed by heparin via the kinetic model of Griffith. In the current model, 
value of most parameters are available from literatures.  
17 
 
Figure 13 Schematic depiction of the thrombosis model, comprised of platelet deposition, aggregation, and stabilization. RP: resting 
platelet, AP: activated platelet, RPd and APd: deposited resting and active platelets, APs: stabilized deposited active platelets. Agonists that 
cause activation (RP to AP) are adenosine diphosphate, ADP; thromboxane A2, TxA2; shear, and thrombin, TB – which is synthesized from 
prothrombin (PT). The suffix b refers to the reaction with the boundary (surface.) The constants kpa, kra, kaa, krpd,b, kapd,b, refer to the 
reaction rates for inter-conversion of the associated platelet states. 
Figure 1 depicts the fundamental mechanisms that comprise the thrombosis model, which include:  
1. Platelet Activation: RP can be converted to be AP through exposure to shear49 and critical levels of biochemical 
agonists, including ADP59–61, Thrombin62,63 and TxA264,65. It is assumed that this conversion results in the release of 
dense granules (ADP) and causes the platelets to become adherent to biomaterial surfaces and to other platelets. 
2. Platelet Deposition: Both RP and AP in the free stream are able to deposit to a surface, such as a channel wall, 
whereupon they are designated RPd and APd, respectively. This process is mathematically modeled by a reaction flux 
at the boundary.  
3. Thrombus Propagation: When the volume fraction of the deposited platelets (RPd and APd) is greater than a specified 
value, the deposition will propagate downstream. Additional details are provided in Supplemental Appendix.  
4. Thrombus Dissolution or Erosion: Shear stress by the fluid phase is able to clear deposited platelets, thereby simulating 
the process known as surface “washing.” Mathematically, it was modeled by thrombus clearance term which is related 
to shear stress. 
5. Thrombus Stabilization: Newly deposited platelets are converted by a constant rate to be as a solid clot which cannot 
be removed by hydrodynamic force.  
6. Thrombus Inhibition: Anti-thrombin III in the free stream and within the thrombus may bind to thrombin, thereby 
neutralizing the effect of thrombin in activating additional platelets. 
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7. Thrombus-fluid interaction: The permeability of thrombus is inversely related to the volume fraction of deposited 
platelets. As represented in Equation (2) above, this is computed as a resistance force to fluid flow, analogous to the 
behavior of packed granular slurries.  
The transport of the above species in the flow field is described by a corresponding set of CDR equations 13,14 of the form: 
𝜕[𝐶𝑖]
𝜕𝑡
+ 𝑑𝑖𝑣(𝒗𝑓 ∙ [𝐶𝑖]) = 𝑑𝑖𝑣(𝐷𝑖 ∙ ∇[𝐶𝑖]) + 𝑆𝑖 (5) 
where [𝐶𝑖] is the concentration of species i; 𝐷𝑖  refers to the diffusivity of species i in blood; and 𝑆𝑖  is a reaction source term for 
species i. Deposited platelets (RPd, APd, and APs) are governed by corresponding rate equations: 
𝜕[𝐶𝑖]
𝜕𝑡
= 𝑆𝑖 (6) 
Table 2 and Table 3 lists the appropriate form for the source terms 𝑆𝑖, along with the abbreviations and the Table 5 shows the 
units, diffusion coefficients and normal level of concentrations for [𝐶𝑖].  
Table 2. Source terms associated with platelets. See Figure 1 for definition of reaction rates, k.  
Species [𝐶𝑖] abbreviation 𝑆𝑖 form 
Unactivated Resting PLTs [RP] −𝑘𝑎𝑝𝑎[𝑅𝑃] − 𝑘𝑠𝑝𝑎[𝑅𝑃] − 𝑘𝑟𝑝𝑑[𝑅𝑃] 
Activated PLTs [AP] 𝑘𝑎𝑝𝑎[𝑅𝑃] + 𝑘𝑠𝑝𝑎[𝑅𝑃] − 𝑘𝑎𝑝𝑑[𝐴𝑃] 
Deposited Resting PLTs [RPd] 
(1 − 𝜃)𝑘𝑟𝑝𝑑[𝑅𝑃]
− 𝑘𝑎𝑝𝑎[𝑅𝑃𝑑] − 𝑘𝑠𝑝𝑎[𝑅𝑃𝑑] − 𝑓𝑒𝑚𝑏[𝑅𝑃𝑑] 
Deposited Activated PLTs [APd] 
𝜃𝑘𝑟𝑝𝑑[𝑅𝑃] + 𝑘𝑎𝑝𝑑[𝐴𝑃]
+ 𝑘𝑎𝑝𝑎[𝑅𝑃𝑑] + 𝑘𝑠𝑝𝑎[𝑅𝑃𝑑] − (𝑓𝑒𝑚𝑏 + 𝑓𝑠𝑡𝑏)[𝐴𝑃𝑑] 
Deposited and stabilized 
PLTs 
[APs] 𝑓𝑠𝑡𝑏[𝐴𝑃𝑑] 
 
Table 3. Source terms for chemical species of the model.  
Species [𝐶𝑖] abbreviation 𝑆𝑖 form 
PLT-released agonists 
(ADP) 
[apr] 
𝜆𝑗(𝑘𝑎𝑝𝑎[𝑅𝑃] + 𝑘𝑠𝑝𝑎[𝑅𝑃] + 𝑘𝑎𝑝𝑎[𝑅𝑃𝑑] + 𝑘𝑠𝑝𝑎[𝑅𝑃𝑑]
+ 𝜃𝑘𝑟𝑝𝑑[𝑅𝑃]) − 𝑘1,𝑗[apr] 
PLT-synthesized agonists 
(TxA2) 
[aps] 𝑠𝑝𝑗([𝐴𝑃] + [𝐴𝑃𝑑]) − 𝑘1,𝑗 ∙ [aps] 
Prothrombin [PT] −𝜀[PT](𝜙𝑎𝑡([𝐴𝑃] + [𝐴𝑃𝑑]) + 𝜙𝑟𝑡([𝑅𝑃] + [𝑅𝑃𝑑])) 
Thrombin [TB] 
−Γ ∙ [𝑇𝐵] + [PT](𝜙𝑎𝑡([𝐴𝑃] + [𝐴𝑃𝑑])
+ 𝜙𝑟𝑡([𝑅𝑃] + [𝑅𝑃𝑑])) 
ATIII [AT] −Γ ∙ 𝜀[𝑇𝐵] 
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Adhesion of platelets to surfaces and all the other species reactions at a boundary are modeled by surface-flux boundary 
conditions, following the approach of Sorensen et al. 13,14. These are listed in Table 4. The specific values and expressions of 
all the source terms and their parameters are provided in the Table 6. It should be mentioned that for different specific studies 
the only parameters that need to be determined are the three material surface-specific coefficients, namely 𝑘𝑟𝑝𝑑,𝑏, 𝑘𝑎𝑝𝑑,𝑏 and 
𝜏𝑒𝑚𝑏,𝑏. Here, similar to the reaction terms in the internal domain, a negative flux implies consumption and a positive flux 
implies generation. 
Table 4(a). Boundary conditions. 
Species [𝐶𝑖] 𝑗𝑖 form Description 
[RP] −𝑆𝑘𝑟𝑝𝑑𝑏[𝑅𝑃] 
Consumption due to [RP]-surface 
adhesion; Generation due to shear 
embolization. 
[AP] −𝑆𝑘𝑎𝑝𝑑𝑏[𝐴𝑃] 
Consumption due to [AP]-surface 
adhesion; Generation due to shear 
embolization. 
[apr] 𝜆𝑗(𝑘𝑎𝑝𝑎[𝑅𝑃𝑑] + 𝑘𝑠𝑝𝑎[𝑅𝑃𝑑] + 𝜃𝑆𝑘𝑟𝑝𝑑𝑏[𝑅𝑃]) 
Generation due to agonists and shear 
activation of [RPd]; Generation due to 
surface contact activation of [RP]-surface 
adhesion. 
[aps] 𝑠𝑝𝑗[𝐴𝑃𝑑] 
Platelet-synthesized generation due to 
[APd] 
[PT] −𝜀[PT](𝜙𝑎𝑡[𝐴𝑃𝑑] + 𝜙𝑟𝑡[𝑅𝑃𝑑]) 
Consumption due to thrombin, [TB], 
generation. 
[TB] [PT](𝜙𝑎𝑡[𝐴𝑃𝑑] + 𝜙𝑟𝑡[𝑅𝑃𝑑]) 
Generation from prothrombin [PT] due to 
deposited platelets. 
[AT] 0.0 No reaction flux. 
 
Table 4(b) Species boundary conditions. (See Table 6 definitions of each of the terms.) 
Species [𝐶𝑖] 𝑗𝑖 form Description 
[RPd] 
∫ (1 − 𝜃)𝑆𝑘𝑟𝑝𝑑𝑏[𝑅𝑃] − 𝑘𝑎𝑝𝑎[𝑅𝑃𝑑]
t
0
− 𝑘𝑠𝑝𝑎[𝑅𝑃𝑑] − 𝑓𝑒𝑚𝑏𝑏[𝑅𝑃𝑑]𝑑𝑡 
Generation due to [RP]-surface adhesion; 
Consumption due to agonists and shear 
activation; Consumption due to shear 
embolization. 
[APd] 
∫ 𝑆𝑘𝑎𝑝𝑑𝑏[𝐴𝑃] + 𝜃𝑆𝑘𝑟𝑝𝑑𝑏[𝑅𝑃]
𝑡
0
+ 𝑘𝑎𝑝𝑎[𝑅𝑃𝑑] + 𝑘𝑠𝑝𝑎[𝑅𝑃𝑑]
− (𝑓𝑒𝑚𝑏𝑏 + 𝑓𝑠𝑡𝑏)[𝐴𝑃𝑑]𝑑𝑡 
Generation due to [AP]-Surface adhesion; 
Generation due to surface contact 
activation of [RP]-Surface adhesion; 
Generation due to agonists and shear 
activation of [RP]; Consumption due to 
shear embolization and stabilization. 
[APs] ∫ 𝑓𝑠𝑡𝑏[𝐴𝑃𝑑]
𝑡
0
𝑑𝑡 Generation due to stabilization. 
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The above equations were numerically simulated using the solvers and the libraries of OpenFOAM, a C++ toolbox66. The 
model was then evaluated for two benchmark problems: (1) growth of mural thrombus in an injured blood vessel and (2) 
deposition within a rectangular crevice. For each geometry studied, the domain was discretized as hexahedral meshes using 
ICEM. In each of the cases, mesh-dependence studies were performed to assure insensitivity to the mesh size. Numerical results 
were visualized with ParaView, a post-processing utility for the solution of continuum mechanics problems. 67 
Table 5. Species units, coefficient of species diffusion and initial condition. 𝛾 is the local shear rate. For more detail see Sorenson13,14 and 
Goodman 21. 
Species Species units 𝐷𝑖(𝑚
2𝑠−1) Initial (inlet) condition in blood 
[RP] PLT m−3  1.58 × 10−13 + 6.0 × 10−13𝛾 
1.5 × 1014 − 3.0 × 1014(Human) 
1.9 × 1014 − 10.0 × 1014(Mouse) 
[AP] PLT m−3  1.58 × 10−13 + 6.0 × 10−13𝛾 0.01[RP] − 0.05[RP] 
[apr] nmol m−3 2.57 × 10−10 0.0 
[aps] nmol m−3 2.14 × 10−10 0.0 
[PT] nmol m−3 3.32 × 10−11 1.1 × 106 
[TB] Um−3 4.16 × 10−11 0.0 
[AT] nmol m−3 3.49 × 10−11 2.844 × 106 
[RPd] PLT m−3 N/A 0.0 
[APd] PLT m−3 N/A 0.0 
[APs] PLT m−3 N/A 0.0 
 
Table 6. Value or expression and description of reaction terms and parameters in current paper.  
Terms Value or expression units Description 
𝑘𝑎𝑝𝑎 
{
 
 
 
 
0, Ω < 1.0
Ω
𝑡𝑐𝑡
, Ω ≥ 1.0
1
𝑡𝑎𝑐𝑡
,
Ω
𝑡𝑐𝑡
≥
1
𝑡𝑎𝑐𝑡
 (s−1) 
Platelets activation due to agonists; 𝑡𝑐𝑡 is the 
characteristic time, which can be used for 
adjusting the activation rate, and here we 
choose 𝑡𝑐𝑡 = 1𝑠 as provided Sorensen 
13,14; 
(𝑘𝑎𝑝𝑎 =
1
𝑡𝑎𝑐𝑡
,
Ω
𝑡𝑐𝑡
≥
1
𝑡𝑎𝑐𝑡
) implies the reaction 
cannot be faster than platelets physical 
activation procedure and 99% platelets will be 
activated during the activation procedure if the 
agonists or shear stress is large enough. 𝑡𝑎𝑐𝑡  is 
the characteristic time; 𝑡𝑎𝑐𝑡 is suggested to 
range from 0.1s to 0.5s considering the results 
by Frojmovic et. al 68 and Richardson 69. 
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Ω ∑𝑤𝑗
𝑛𝑎
𝑗=1
𝑎𝑗
𝑎𝑗,𝑐𝑟𝑖𝑡
 (N/A) 
𝑎𝑗 refers to the concentration of ADP, TxA2 and 
Thrombin. Value of 𝑤𝑗  and 𝑎𝑗,𝑐𝑟𝑖𝑡  see Table 7 
𝑘𝑠𝑝𝑎 
1
𝑡𝑐𝑡,𝑠𝑝𝑎
=
{
 
 
1
4.0 × 106𝜏−2.3
, 𝑡𝑐𝑡,𝑠𝑝𝑎 > 𝑡𝑎𝑐𝑡
1
𝑡𝑐𝑡,𝑠𝑝𝑎
, 𝑡𝑐𝑡,𝑠𝑝𝑎 < 𝑡𝑎𝑐𝑡
 
(s−1) 
Platelet activation due to shear stress, 𝜏. 
Expression 𝑡𝑐𝑡,𝑠𝑝𝑎 = 4.0 × 10
6𝜏−2.3 was 
provided by Goodman21 and Hellums70. 
𝑘𝑟𝑝𝑑 𝑑𝑖𝑣(𝑘𝑝𝑑,𝑓?⃗? )𝑘𝑟𝑎 (s
−1) 
Unactivated platelets - deposited activated 
platelets ([RP]-[APd]), deposition rate. 𝑓 refers 
to the face of a mesh cell and ?⃗?  is the unit 
normal to the face. Details about how this term 
is calculated are provided in Supplemental 
Appendix. 
𝑘𝑟𝑎 3.0 × 10
−6 (m s−1) Constant related to 𝑘𝑟𝑝𝑑.
13,14 
𝑘𝑎𝑝𝑑 𝑑𝑖𝑣(𝑘𝑝𝑑,𝑓?⃗? )𝑘𝑎𝑎 (s
−1) 
Activated platelets-deposited activated platelets 
([AP]-[APd]) deposition rate. Details about how 
this term is calculated are provided in 
Supplemental Appendix. 
𝑘𝑎𝑎 3.0 × 10
−5 (m s−1) Constant related to 𝑘𝑎𝑝𝑑. 
13,14 
𝑓𝑒𝑚𝑏  
𝐷𝑖𝑎𝑃𝐿𝑇 ∙ 𝑑𝑖𝑣(𝑘𝑒𝑚𝑏,𝑓?⃗⃗? )
∙ (1 − 𝑒𝑥𝑝(−0.0095
𝜏
𝜏𝑒𝑚𝑏
 )) 
s−1 
Platelet embolization due to shear stress; 
Expression 𝑒𝑥𝑝(−0.0095𝜏 ) was suggested by 
Goodman21. 𝐷𝑖𝑎𝑃𝐿𝑇 = 2.78 × 10
−6𝑚 is the 
hydraulic diameter of platelets. 
𝑘𝑒𝑚𝑏,𝑓 𝑘𝑒𝑚𝑏,𝑓 = {
1, 𝑘𝑝𝑑,𝑓 > 0 
0, 𝑘𝑝𝑑,𝑓 = 0
 s−1  
𝜏𝑒𝑚𝑏 30 𝑑𝑦𝑛𝑒 𝑐𝑚
−2 Platelet shear embolization related constant.21 
𝑓𝑒𝑚𝑏𝑏  (1 − 𝑒𝑥𝑝(−0.0095
𝜏
𝜏𝑒𝑚𝑏𝑏
 )) s−1 
Platelet embolization in boundary due to shear 
stress. 
𝜏𝑒𝑚𝑏𝑏  
To be determined, depends on 
bio-material. 
𝑑𝑦𝑛𝑒 𝑐𝑚−2 Platelet shear embolization related constant. 
𝑃𝐿𝑇𝑚𝑎𝑥  
𝑃𝐿𝑇𝑠,𝑚𝑎𝑥
𝐷𝑖𝑎𝑃𝐿𝑇
 PLT m−3 
The maximum concentration of platelets in 
space.𝑃𝐿𝑇𝑠,𝑚𝑎𝑥 = 7 × 10
10𝑃𝐿𝑇𝑚−2 is the total 
capacity of the surface for platelets; 𝐷𝑖𝑎𝑃𝐿𝑇 =
2.78 × 10−6𝑚. 
𝜆𝑗 2.4 × 10−8 nmol PLT−3 The amount of agonist j released per platelet. 
𝜃 1.0 (N/A) Platelets activation by contact. 
𝑘1,𝑗 {
0.0161 for TxA2
0.0 for ADP
 (s−1) The inhibition rate constant of agonist. 
𝑠𝑝𝑗 {
9.5 × 10−12 for TxA2
0.0 for ADP
 nmol PLT−3 s−1 The rate constant of synthesis of an agonist. 
𝜀 9.11 × 10−3 nmol U−1 Unit conversion. From NIH units to SI units. 
𝜙𝑎𝑡 3.69 × 10
−15 
m3 nmol−1 
 PLT−1 U s−1 
Thrombin generation rate on the surface of 
activated platelets 
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𝜙𝑟𝑡 6.5 × 10
−16 
m3 nmol−1 
 PLT−1 U s−1 
Thrombin generation rate on the surface of 
unactivated platelets 
Γ 
𝑘1,𝑇[𝐻][𝐴𝑇]
𝛼𝐾𝐴𝑇𝐾𝑇 + 𝛼𝐾𝐴𝑇𝜀[𝑇𝐵] + [𝐴𝑇]𝜀[𝑇𝐵]
 (s−1) 
Griffith’s template model for the kinetics of the 
heparin-catalyzed inactivation of thrombin by 
ATIII. 
𝑘1,𝑇 13.333 (s−1) A first-order rate constant. 
[𝐻] 0.1 × 106 nmol m−3 
Heparin concentration, assuming specific 
activity of 300 U mg-1 and molecular weight of 
16 kDa.14,71 
𝛼 1.0 (N/A) 
A factor to simulate a change in affinity of 
heparin for ATIII when it is bound to thrombin 
or for thrombin when it is bound to ATIII. 
𝐾𝐴𝑇 0.1 × 106 nmol m−3 The dissociation constant for heparin/ATIII. 
𝐾𝑇 3.50 × 10
4 nmol m−3 The dissociation constant for heparin/thrombin. 
𝑆 1 −
[𝑅𝑃𝑑𝑏] + [𝐴𝑃𝑑𝑏] + [𝐴𝑃𝑠𝑏]
𝑃𝐿𝑇𝑠,𝑚𝑎𝑥
 (N/A) 
Percentage of the wall (boundary) not been 
occupied by deposited platelets. 
𝑘𝑟𝑝𝑑𝑏 
To be determined, depends on 
bio-material. 
(m s−1) 
Unactivated platelet-boundary(wall) deposition 
rate. 
𝑘𝑎𝑝𝑑𝑏 
To be determined, depends on 
bio-material. 
(m s−1) 
Activated platelet-boundary(wall) deposition 
rate. 
𝑓𝑠𝑡𝑏 0.0 (s
−1) Deposited activated platelet stabilization rate. 
𝜙 
𝑅𝑃𝑑 + 𝐴𝑃𝑑 + 𝐴𝑃𝑠
𝑃𝐿𝑇𝑚𝑎𝑥
 (N/A) Volume fraction of deposited platelets 
Table 7. Threshold concentration of that agonist for platelet activation and agonist-specific weight13,14,21. It should be noticed that the 
threshold of the agonist may vary for some certain according to different experimental studies. For ADP see 68,72–75; for Thrombin see 76–78; 
for TxA2 see 79–81. 
Species 𝑎𝑗,𝑐𝑟𝑖𝑡 𝑤𝑗  
ADP([apr]) 1.00 × 106nmol m−3 1 
TxA2([aps]) 0.20 × 106nmol m−3 3.3 
Thrombin([TB]) 0.1 × 106Um−3 30 
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Appendix 1. Governing questions of chemical/biological species 
Provided below are the full set of governing equations in expanded form.  
Unactivated resting PLTs in flow ([RP]) 
𝜕[𝑅𝑃]
𝜕𝑡
+ 𝑑𝑖𝑣(𝒗𝑓 ∙ [𝑅𝑃]) = 𝑑𝑖𝑣(𝐷𝑃 ∙ ∇[𝑅𝑃]) − 𝑘𝑎𝑝𝑎[𝑅𝑃] − 𝑘𝑠𝑝𝑎[𝑅𝑃] − 𝑘𝑟𝑝𝑑[𝑅𝑃] (7) 
where 𝒗𝑓 is the velocity of the fluid (blood), 𝐷𝑃 is the diffusivity of the platelets, 𝑘𝑎𝑝𝑎 and 𝑘𝑠𝑝𝑎 are the platelets activation rate 
due to agonists and shear stress, and 𝑘𝑟𝑝𝑑 is the deposition rate between [RP] and deposited platelets. The detail definition of 
the 𝑘𝑟𝑝𝑑 in mathematical and numerical see Appendix 2.  
Activated platelets in flow [AP] 
𝜕[𝐴𝑃]
𝜕𝑡
+ 𝑑𝑖𝑣(𝒗𝑓 ∙ [𝐴𝑃]) = 𝑑𝑖𝑣(𝐷𝑃 ∙ ∇[𝐴𝑃]) + 𝑘𝑎𝑝𝑎[𝑅𝑃] + 𝑘𝑠𝑝𝑎[𝑅𝑃] − 𝑘𝑎𝑝𝑑[𝐴𝑃] (8) 
where 𝑘𝑎𝑝𝑑 is the deposition rate between [AP] and deposited platelets. The detail definition of the 𝑘𝑎𝑝𝑑 in mathematical and 
numerical see Appendix 2. 
Deposited resting platelets [RPd] 
𝜕[𝑅𝑃𝑑]
𝜕𝑡
= (1 − 𝜃)𝑘𝑟𝑝𝑑[𝑅𝑃] − 𝑘𝑎𝑝𝑎[𝑅𝑃𝑑] − 𝑘𝑠𝑝𝑎[𝑅𝑃𝑑] − 𝑓𝑒𝑚𝑏[𝑅𝑃𝑑] (9) 
where (1 − 𝜃)𝑘𝑟𝑝𝑑[𝑅𝑃] is the percentage of [RP] activated by contact with biomaterial surfaces and formatted thrombus, 𝑓𝑒𝑚𝑏  
is the cleaning rate of deposited platelets due to shear stress. 
Deposited activated platelets [APd] 
𝜕[𝐴𝑃𝑑]
𝜕𝑡
= 𝜃𝑘𝑟𝑝𝑑[𝑅𝑃] + 𝑘𝑎𝑝𝑑[𝐴𝑃] + 𝑘𝑎𝑝𝑎[𝑅𝑃𝑑] + 𝑘𝑠𝑝𝑎[𝑅𝑃𝑑] − (𝑓𝑒𝑚𝑏 + 𝑓𝑠𝑡𝑏)[𝐴𝑃𝑑] (10) 
where 𝑓𝑠𝑡𝑏 is the stabilization rate parameter of [APd], which convert deposited thrombus to be stabilized thrombus which is 
harder to be cleaned by shear stress. 
Deposited and stabilized platelets [APs] 
𝜕[𝐴𝑃𝑠]
𝜕𝑡
= 𝑓𝑠𝑡𝑏[𝐴𝑃𝑑] (11) 
PLT-released agonists (ADP) [𝐚𝐩𝐫] 
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𝜕[apr]
𝜕𝑡
+ 𝑑𝑖𝑣(𝒗𝑓 ∙ [apr]) = 𝑑𝑖𝑣(𝐷𝑎𝑝𝑟 ∙ ∇[apr])
+ 𝜆𝑗(𝑘𝑎𝑝𝑎[𝑅𝑃] + 𝑘𝑠𝑝𝑎[𝑅𝑃] + 𝑘𝑎𝑝𝑎[𝑅𝑃𝑑] + 𝑘𝑠𝑝𝑎[𝑅𝑃𝑑] + 𝜃𝑘𝑟𝑝𝑑[𝑅𝑃]) − 𝑘1,𝑗[apr] 
(12) 
where 𝜆𝑗 is the amount of agonist j released per platelet and 𝑘1,𝑗 is the inhibition rate constant of agonist j; and j represents 
ADP for current specie. Therefore 𝜆𝑗𝑘𝑎𝑝𝑎[𝑅𝑃]  and 𝜆𝑗𝑘𝑎𝑝𝑎[𝑅𝑃𝑑]  are the ADP releasing attributed to the activation of 
unactivated platelets due to agonist, 𝜆𝑗𝑘𝑠𝑝𝑎[𝑅𝑃]  and 𝜆𝑗𝑘𝑠𝑝𝑎[𝑅𝑃𝑑]  are the ADP releasing attributed to the activation of 
unactivated platelets due to shear stress and 𝜆𝑗𝜃𝑘𝑟𝑝𝑑[𝑅𝑃] represents the ADP releasing attributed to the platelets activation due 
to contact. 𝑘1,𝑗[apr] is the inhibition rate of ADP. 
PLT-synthesized agonists (TxA2) [𝐚𝐩𝐬] 
𝜕[aps]
𝜕𝑡
+ 𝑑𝑖𝑣(𝒗𝑓 ∙ [aps]) = 𝑑𝑖𝑣(𝐷𝑎𝑝𝑠 ∙ ∇[aps]) + 𝑠𝑝𝑗([𝐴𝑃] + [𝐴𝑃𝑑]) − 𝑘1,𝑗 ∙ [aps] (13) 
where 𝑠𝑝𝑗 is the rate constant of synthesis of the agonist j; and j represents TxA2 for current specie. Therefore 𝑠𝑝𝑗[𝐴𝑃] and 
𝑠𝑝𝑗[𝐴𝑃𝑑] represent the rate of synthesis of TxA2 due to activated platelets in flow and deposited activated platelets. 𝑘1,𝑗 ∙ [aps] 
is the inhibition rate of TxA2. 
Prothrombin [PT] 
𝜕[PT]
𝜕𝑡
+ 𝑑𝑖𝑣(𝒗𝑓 ∙ [PT]) = 𝑑𝑖𝑣(𝐷𝑃𝑇 ∙ ∇[PT]) − 𝜀[PT](𝜙𝑎𝑡([𝐴𝑃] + [𝐴𝑃𝑑]) + 𝜙𝑟𝑡([𝑅𝑃] + [𝑅𝑃𝑑])) (14) 
where 𝜀 is the unit conversion which is from NIH units to SI units, 𝜙𝑎𝑡 and 𝜙𝑟𝑡 are the thrombin generation rate constant on 
the surface of activated platelets and unactivated resting platelets. Therefore 𝜙𝑎𝑡[𝐴𝑃] and 𝜙𝑟𝑡[𝑅𝑃] are the thrombin generation 
rate due to activated and resting platelets in flow, while 𝜙𝑎𝑡[𝐴𝑃𝑑] and 𝜙𝑟𝑡[𝑅𝑃𝑑] are the thrombin generation rate due to 
deposited activated and unactivated platelets. 
Thrombin [TB] 
𝜕[𝑇𝐵]
𝜕𝑡
+ 𝑑𝑖𝑣(𝒗𝑓 ∙ [𝑇𝐵]) = 𝑑𝑖𝑣(𝐷𝑇𝐵 ∙ ∇[𝑇𝐵]) + [PT](𝜙𝑎𝑡([𝐴𝑃] + [𝐴𝑃𝑑]) + 𝜙𝑟𝑡([𝑅𝑃] + [𝑅𝑃𝑑])) − Γ ∙ [𝑇𝐵] (15) 
where Γ is the Griffith’s template model for the kinetics of the heparin-catalyzed inactivation of thrombin by ATIII. Therefore 
Γ ∙ [𝑇𝐵] is the inactivation rate of thrombin by ATIII. 
ATIII [AT] 
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𝜕[𝐴𝑇]
𝜕𝑡
+ 𝑑𝑖𝑣(𝒗𝑓 ∙ [𝐴𝑇]) = 𝑑𝑖𝑣(𝐷𝐴𝑇 ∙ ∇[𝐴𝑇]) − Γ ∙ 𝜀[𝑇𝐵] (16) 
where Γ ∙ 𝜀[𝑇𝐵] is the consumption rate of ATIII due to inactivation of thrombin. 
Appendix 2. Mathematical and Numerical Considerations for Deposition Rates krpd and kapd. 
Provided below are mathematical and numerical considerations about the two terms in equations (1) – (4) above, that represent 
the rate of deposition to the surface of the thrombus by unactivated resting platelets (𝑘𝑟𝑝𝑑) and activated platelets (𝑘𝑎𝑝𝑑) in the 
free stream. Referring to the finite volume schematic depicted in Figure S1, the 𝑘𝑟𝑝𝑑 of the finite-volume-cell 5 is calculated 
as 
𝑘𝑟𝑝𝑑 = 𝑑𝑖𝑣(𝑘𝑝𝑑,𝑓?⃗? )𝑘𝑟𝑎 (17) 
where kra is a constant, ?⃗?  is the normal to the finite-volume-face, and 𝑓 refers to the faces shared by adjacent cells 2, 4, 6 and 
8. Assuming that thrombus tends to grow layer by layer, when the volume fraction of the deposited platelets of a finite-volume 
cell 𝜙 is greater than a critical value 𝜙𝑐 (for example, 0.74, which is the maximum packing fraction for spheres), this cell is 
able to influence the neighbor cells. Therefore 
𝑘𝑝𝑑,𝑓 = {
[𝐴𝑃𝑑]𝑓
𝑃𝐿𝑇𝑚𝑎𝑥
, 𝜙 > 𝜙𝑐 
0, 𝜙 < 𝜙𝑐
 (18) 
where 
[𝐴𝑃𝑑]𝑓
𝑃𝐿𝑇𝑚𝑎𝑥
 represents the percentage of the area occupied by deposited activated platelets at that mesh face. This rule does 
not apply to the boundary faces. 
  
Figure S14 Schematic of cells and faces of a mesh. 
 
 
